Sign in Subscribe

Larimar Soars as FDA Grants Breakthrough Status to First Potential Disease-Modifying FA Drug

Larimar shares jump 31% after FDA grants Breakthrough Therapy Designation to nomlabofusp for Friedreich’s ataxia. Company eyes accelerated approval with BLA filing in June 2026.

Larimar Soars as FDA Grants Breakthrough Status to First Potential Disease-Modifying FA Drug
Credit: Larimar Therapeutics
Already have an account? Sign in.